Ayala Pharmaceuticals Inc (fka ADXS)

[fbg0316]

Not flip flopping, still not happy with all the dilution, particularly the dilution to pay management unearned excess bonus compensation, which I think ultimately has lowered the return shareholders will see, but still a tremendous opportunity for the platform and shareholders hopefully will see a great return even if Dan has taken proportionately more than he has earned for himself.